Global Liquid Biopsy Market to Reach $15.46B by 2033, Driven by Innovation

According to Renub Research Latest Report liquid biopsy market is projected to grow from USD 4.29 billion in 2024 to USD 15.46 billion by 2033, representing a robust CAGR of 15.30% between 2025 and 2033. Growth is fueled by rising demand for non-invasive cancer diagnostics, advancements in biomarker technology, and increased adoption of personalized medicine. Liquid biopsies are becoming critical tools for early cancer detection, treatment monitoring, and recurrence tracking, transforming both clinical practice and patient care worldwide.

Liquid Biopsy Market Overview

Liquid biopsy is a non-invasive diagnostic technique that analyzes biological fluids—primarily blood—to detect cancer and other diseases. Unlike traditional tissue biopsies, which require surgical extraction, liquid biopsies leverage circulating biomarkers such as circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells, and exosomes.

The technique is widely employed for early detection of cancer, monitoring disease progression, and evaluating treatment response. Liquid biopsies offer real-time insights into tumor dynamics, minimal risk, faster results, and the ability to track minimal residual disease and cancer recurrence. Beyond oncology, they are being explored in prenatal testing, organ transplant monitoring, and detection of genetic and chronic conditions, positioning them as pivotal in the era of precision medicine.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Key Market Drivers

Rising Cancer Incidence and Chronic Diseases

The increasing prevalence of cancer worldwide is one of the primary growth drivers for liquid biopsies. They offer accurate, efficient, and non-invasive detection of cancers such as lung, breast, and colorectal cancer. Early detection and ongoing monitoring are crucial for improved outcomes, and liquid biopsies provide a safer alternative for patients, particularly those with advanced-stage cancer. Beyond oncology, liquid biopsies are gaining traction in monitoring cardiovascular and genetic diseases, further expanding market opportunities.

For instance, in 2024, the United States anticipates over 2 million new cancer cases and more than 600,000 cancer-related deaths, underscoring the critical need for non-invasive diagnostic solutions.

Technological Advancements in Biomarkers

Breakthroughs in biomarker discovery and molecular diagnostics, including next-generation sequencing (NGS), ctDNA analysis, and exosome profiling, have significantly increased the adoption of liquid biopsies. These technologies enable early disease detection, real-time treatment monitoring, and identification of actionable mutations.

In August 2024, Hitachi High-Tech Corporation partnered with Gencurix, Inc. to establish a cancer molecular diagnostic service, integrating Hitachi’s diagnostic expertise with Gencurix’s biomarker discovery capabilities—a testament to the market’s rapid innovation trajectory.

Shift Toward Non-Invasive Diagnostics

Patients increasingly prefer non-invasive diagnostic techniques due to lower risk, minimal recovery time, and repeatability. Liquid biopsies fit perfectly into outpatient and home-based care settings, supporting patient-centric healthcare approaches. This trend is driving widespread adoption, particularly in advanced-stage cancer management where traditional biopsies may be challenging or risky.

Regional Insights

United States

The United States dominates the liquid biopsy market globally, attributed to high cancer incidence, advanced medical infrastructure, and substantial investment in R&D. FDA clearance of multiple liquid biopsy technologies has accelerated adoption across clinical settings.

In February 2024, Myriad Genetics acquired select assets from Intermountain Health, including the Precise Tumor Test and Precise Liquid Test, strengthening its market position. The US market continues to benefit from ongoing innovation, regulatory support, and increasing patient awareness of non-invasive diagnostic options.

Germany

Germany leads Europe in liquid biopsy adoption due to its robust healthcare system, biotechnology investments, and emphasis on medical research. Regulatory support and precision medicine initiatives further facilitate the adoption of liquid biopsies.

In September 2024, PreAnalytiX GmbH (a joint venture between QIAGEN N.V. and BD) launched the PAXgene Urine Liquid Biopsy Set, enabling reliable cfDNA analysis from urine samples using advanced molecular testing technologies.

China

China’s liquid biopsy market is expanding rapidly, driven by increasing cancer prevalence and government initiatives to improve healthcare infrastructure. The country’s biotechnology sector has engaged in partnerships with global firms to accelerate innovation and early cancer detection.

In August 2023, China’s National Medical Products Administration approved sunvozertinib for patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations, highlighting the country’s commitment to advanced diagnostics and personalized medicine.

Brazil

As the largest Latin American economy, Brazil is leading liquid biopsy adoption in the region. Growing healthcare awareness, government initiatives, and investment in biotechnology support early cancer detection and monitoring. Liquid biopsies are becoming a preferred diagnostic tool due to their non-invasive nature and potential to improve patient outcomes.

Recent Developments in Liquid Biopsy

F. Hoffmann-La Roche Ltd.

October 2020: FDA-approved companion diagnostic (CDx) for non-small cell lung cancer (NSCLC).

June 2022: Partnered with Lung Cancer Research Foundation and Lung Cancer Mutation Consortium for early-stage lung cancer screening.

Thermo Fisher Scientific Inc.

November 2022: Launched digital PCR liquid-biopsy assays for Applied Biosystems absolute Q dPCR system.

September 2021: Collaborated with AstraZeneca to develop NGS-based CDx for targeted therapy.

Guardant Health

January 2023: FDA approval for Guardant360 CDx as a companion diagnostic for ESR1 mutant breast cancer.

February 2021: Launched Guardant Reveal test for residual disease monitoring in early-stage colorectal cancer.

Illumina, Inc.

November 2023: Launched TruSight Oncology 500 ctDNA v2, a next-gen liquid biopsy assay for genomic profiling.

QIAGEN N.V.

May 2023: Introduced Therascreen EGFR Plus RGQ PCR Kit to identify EGFR gene mutations.

January 2022: Biotech Grants program supports global partnerships to expand liquid biopsy capabilities.

Exact Sciences Corporation

January 2022: Expanded diagnostics portfolio by acquiring Prevention Genetics, enabling hereditary cancer testing.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation

By Product Type

Kits & Reagents

Platforms & Instruments

Services

By Application

Cancer Therapeutic Applications

Reproductive Health

Other Therapeutic Uses

By Circulating Biomarker

Circulating Tumor Cells (CTCs)

Circulating Tumor DNA (ctDNA)

Cell-free DNA (cfDNA)

By End User

Hospitals

Diagnostic Laboratories

Point-of-Care Testing

Academic Institutes

Others

By Region

Americas: United States, Canada, Mexico, Brazil

Europe: United Kingdom, Germany, France, Italy, Spain, Netherlands

Asia-Pacific: China, Japan, India, South Korea, Australia

Middle East & Africa: UAE, South Africa

Rest of the World

Key Market Players

F. Hoffmann-La Roche Ltd.

Bio-Rad Laboratories

Thermo Fisher Scientific Inc.

Johnson & Johnson

Biocept Inc.

Guardant Health

Illumina, Inc.

Laboratory Corporation of America Holdings

QIAGEN N.V.

Exact Sciences Corporation

These companies dominate the market through innovation, strategic partnerships, and expansion of liquid biopsy assays and platforms. Their activities focus on enhancing diagnostic accuracy, broadening therapeutic applications, and improving accessibility globally.

Future Outlook

The liquid biopsy market is poised for substantial growth in the coming decade. Rising cancer prevalence, technological innovations, and increasing patient preference for non-invasive diagnostics will continue to drive adoption. Liquid biopsies are expected to expand beyond oncology into areas like prenatal diagnostics, organ transplantation, and chronic disease monitoring.

Technologies such as NGS, digital PCR, and AI-driven biomarker analytics will enhance the sensitivity and specificity of assays, enabling earlier detection, precise therapy selection, and personalized treatment monitoring. Geographically, North America and Europe will continue to lead due to advanced healthcare infrastructure, while Asia-Pacific and Latin America will emerge as high-growth regions driven by increased awareness, investments, and healthcare modernization initiatives.

Collaborations among biotech firms, diagnostics companies, and academic institutions will accelerate product innovation and market penetration. As the field matures, liquid biopsies may become the standard of care for non-invasive diagnostics, transforming disease detection, monitoring, and personalized treatment worldwide.

Conclusion

The global liquid biopsy market is entering a period of unprecedented growth, projected to reach USD 15.46 billion by 2033. Driven by technological advancements, rising cancer incidence, and patient-centric healthcare trends, liquid biopsies are revolutionizing diagnostics and personalized medicine. As innovations continue and adoption spreads across regions, the market will play a critical role in early disease detection, monitoring treatment efficacy, and improving patient outcomes globally.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.